Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Davidson

Showing results (181-190 of 358) with videos related to

Pageof 36
Sort By:
Dialogues in Clinical Neuroscience|March 20, 2025
Exploring novel therapeutic strategies: Could psychedelic perspectives offer promising solutions for Alzheimer's disease comorbidities?Michael Davidson, Gabriela-Dumitrita Stanciu, Jonathan Rabinowitz, et al.
The Journal of Clinical Psychiatry|October 20, 2004
Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidoneJonathan Rabinowitz, Ira R Katz, Peter Paul De Deyn, et al.
Clinical Lung Cancer|October 25, 2023
Smoking, Diabetes Mellitus, and Previous Cardiovascular Disease as Predictors of Anticancer Treatment-Induced Cardiotoxicity in Non-Small-Cell Lung Cancer: A Real-World StudyHasan Kobat, Islam Elkonaissi, Emma Foreman, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|April 21, 2026
Quality of Life in early-phase schizophrenia patients starting treatment with long-acting injectable vs. oral antipsychotic drugs: data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)Anna-Theresa Schulze, Lena Tschiderer, Fabienne Post, et al.
Biological Psychiatry|April 13, 2015
The puzzle of processing speed, memory, and executive function impairments in schizophrenia: fitting the pieces togetherEmma E M Knowles, Mark Weiser, Anthony S David, et al.
The American Journal of Cardiology|January 26, 2002
Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemiaMichael Davidson, Patrick Ma, Evan A Stein, et al.
World Journal of Gastrointestinal Oncology|September 5, 2017
Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancerMichael Davidson, Ian Chau, David Cunningham, et al.
Schizophrenia Research|September 7, 2019
Effects of Roluperidone (MIN-101) on two dimensions of the negative symptoms factor score: Reduced emotional experience and reduced emotional expressionPhilip D Harvey, Jay B Saoud, Remy Luthringer, et al.
Schizophrenia Research|September 18, 2010
CNS infection in childhood does not confer risk for later schizophrenia: a case-control studyMark Weiser, Nomi Werbeloff, Arie Levine, et al.
Schizophrenia Research|October 13, 2009
Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST)Han Boter, Joseph Peuskens, Jan Libiger, et al.
Pageof 36

Showing results (181-190 of 358) with videos related to

Sort By:
Pageof 36
Dialogues in Clinical Neuroscience|March 20, 2025
Exploring novel therapeutic strategies: Could psychedelic perspectives offer promising solutions for Alzheimer's disease comorbidities?Michael Davidson, Gabriela-Dumitrita Stanciu, Jonathan Rabinowitz, et al.
The Journal of Clinical Psychiatry|October 20, 2004
Behavioral and psychological symptoms in patients with dementia as a target for pharmacotherapy with risperidoneJonathan Rabinowitz, Ira R Katz, Peter Paul De Deyn, et al.
Clinical Lung Cancer|October 25, 2023
Smoking, Diabetes Mellitus, and Previous Cardiovascular Disease as Predictors of Anticancer Treatment-Induced Cardiotoxicity in Non-Small-Cell Lung Cancer: A Real-World StudyHasan Kobat, Islam Elkonaissi, Emma Foreman, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|April 21, 2026
Quality of Life in early-phase schizophrenia patients starting treatment with long-acting injectable vs. oral antipsychotic drugs: data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)Anna-Theresa Schulze, Lena Tschiderer, Fabienne Post, et al.
Biological Psychiatry|April 13, 2015
The puzzle of processing speed, memory, and executive function impairments in schizophrenia: fitting the pieces togetherEmma E M Knowles, Mark Weiser, Anthony S David, et al.
The American Journal of Cardiology|January 26, 2002
Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemiaMichael Davidson, Patrick Ma, Evan A Stein, et al.
World Journal of Gastrointestinal Oncology|September 5, 2017
Impact of tumour histological subtype on chemotherapy outcome in advanced oesophageal cancerMichael Davidson, Ian Chau, David Cunningham, et al.
Schizophrenia Research|September 7, 2019
Effects of Roluperidone (MIN-101) on two dimensions of the negative symptoms factor score: Reduced emotional experience and reduced emotional expressionPhilip D Harvey, Jay B Saoud, Remy Luthringer, et al.
Schizophrenia Research|September 18, 2010
CNS infection in childhood does not confer risk for later schizophrenia: a case-control studyMark Weiser, Nomi Werbeloff, Arie Levine, et al.
Schizophrenia Research|October 13, 2009
Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST)Han Boter, Joseph Peuskens, Jan Libiger, et al.
Pageof 36